ClinicalTrials.gg
CompletedNCT00757627Updated Feb 9, 2022Results posted

Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

A Phase 4 interventional study of etoricoxib in Pain, sponsored by Organon and Co. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing etoricoxib in Pain — none open to participants now, 1 under way, none of them phase 3. Etoricoxib · Pain.

Enrollment
2nd of 14
500 · median 75
Started
2007
the only one that year
Phase 4
9 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
3 of 14
Organon and Co

Among the 14 studies testing etoricoxib in Pain, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 9 in phase 4, and was the 5th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 14 studies testing etoricoxib in Pain is open now. The open studies under Pain, anywhere →

About etoricoxib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing etoricoxib in Pain as a file.
02

Study summary

The purpose of this study is to collect disease burden of OA and the effectiveness and patient satisfaction of treatment by Etoricoxib in the normal practice setting.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must Be Over 20 Years Of Age, Regardless Of Sex
  • Must Have A Diagnosis Of OA That Requiring Treatment
  • Patients Must Have Taken an NSAID, Cox-2 Or Opioids On The Majority Of Days During The Last 4 Weeks Before Enrollment Who Are Intolerant (Due To Gastrointestinal Adverse Events) Or Inadequately Respond To Current Therapy (Vas >= 40 mm On A Pain Scale From 0-100 mm)
  • Excluding Osteoarthritis, The Patient Is Judged To Be In Otherwise General Good Health Based On Medical History, Physical Examination, And Routine Laboratory Tests
  • Must Agree To Participate Voluntarily In The Study
  • Must Have The Capacity To Understand And Answer The Questionnaires Used In The Study
  • Must Agree To Return For A Follow-Up Visit With The Treating Physician Four Weeks After The Initiation Of Treatment With Etoricoxib
  • Patient Is Willing To Sign Form

Exclusion criteria

Exclusion Criteria:

  • Under 20 Years Of Age
  • Severe Hepatic Insufficiency ( Score > 9)
  • Advanced Renal Insufficiency ( \< 30 Ml/Min)
  • Any Or Warning Or Precaution As Mentioned In The Approved Study Drug Package Insert
  • Gi Ulcer With Active Bleeding Present At Study Enrollment
  • Patient Has A Recent History Of Stroke, Myocardial Infarction Or (Within The Previous 2 Years)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    1

    Etoricoxib

    Drug: etoricoxib

Interventions

  • etoricoxib 60 mg QD for 4 weeks.

    Also known as: Arcoxia

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 4

    WOMAC for pain assessment by patient (0-100 mm Visual Analog Scale (VAS) with 0 represent "no pain" and 100 represent "extreme pain")

    Time frame: Baseline and end of week 4

Secondary outcomes

  1. Mean Change From Baseline in Patient WOMAC Domain Scores at Week 4

    The change from baseline in 3 domain scores (pain, stiffness, and difficult in doing daily activity) of WOMAC at week 4 were measured. Each domain comprises of questions and VAS scales for scoring. For pain domain, 0 represents no pain and 100 represents extreme pain; for stiffness domain, 0 represents no stiffness and 100 represents extreme stiffness; for difficult in doing daily activity domain, 0 represents no difficulty and 100 represents most difficulty.

    Time frame: Baseline and Week 4

  2. Physicians' Global Assessment of Patients' Response to Therapy at Baseline Using IGART (Investigator Global Assessment of Response to Therapy)

    The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants who met the criteria of any of the 5 categories at baseline were collected.

    Time frame: Baseline

  3. Physicians' Global Assessment of Patients' Response to Therapy at Week 4 Using IGART

    The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants met the criteria of any of the 5 categories at week 4 were collected.

    Time frame: Week 4

  4. Patient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Baseline

    The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[Not present, moderate and extreme\] for discomfort and anxiety/depression.

    Time frame: Baseline

  5. Patient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Week 4

    The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[ Not present, moderate and extreme\]for discomfort and anxiety/depression

    Time frame: Week 4

  6. Change From Baseline of Patient BPI (Brief Pain Inventory) Scores at Week 4

    BPI consists of pain and pain interference domains. For pain (0=no pain to 10=extreme pain); for pain interference ( 0=no interference to 10= greatest interference).

    Time frame: Baseline and Week 4

  7. Changes From Baseline in Patient TSQM (Treatment Satisfaction Questionnaire for Medication) Domain Scores at Week 4

    TSQM consists of four domains (effectiveness; side effect; convenience and overall satisfaction), domain scores ranged from 0 (0=worst) to 100 (100=best) were derived from converting the original Likert's scales to VAS scale.

    Time frame: Baseline and Week 4

  8. Change From Baseline in Number of Days Patient Miss From Work or House Keeping Work at Week 4

    Time frame: Baseline and Week 4

  9. Change From Baseline in Patient-SF36 (Short Form 36) Domain Scores at Week 4

    Weighted scores of the 8 domains of SF36 (i.e., physical functioning; role limiting due to physical problem; bodily pain; general health; vitality; social functioning; role limiting due to emotional problem; mental health) were scored on a scale from 0 \~100, with 100 representing the best possible functioning)

    Time frame: Baseline and Week 4

07

Results

Posted May 11, 2010
Limitations and caveats
Open-labeled, non-controlled

Participant flow

Participant flow — Overall Study
MilestoneEtoricoxib
Started500
Completed419
Not completed81
Withdrew: Adverse event15
Withdrew: Lack of efficacy10
Withdrew: Lost to follow-up28
Withdrew: Withdrawal by subject27
Withdrew: Other1

Outcome measures

SecondaryMean Change From Baseline in Patient WOMAC Domain Scores at Week 4

The change from baseline in 3 domain scores (pain, stiffness, and difficult in doing daily activity) of WOMAC at week 4 were measured. Each domain comprises of questions and VAS scales for scoring. For pain domain, 0 represents no pain and 100 represents extreme pain; for stiffness domain, 0 represents no stiffness and 100 represents extreme stiffness; for difficult in doing daily activity domain, 0 represents no difficulty and 100 represents most difficulty.

Time frame:
Baseline and Week 4
Reported as:
Mean · Units on a Scale
Mean Change From Baseline in Patient WOMAC Domain Scores at Week 4
Units on a ScaleEtoricoxib
WOMAC Pain subscale (n=418)-10.0 ± 20.5
WOMAC Stiffness subscale (n=418)-7.9 ± 25.7
WOMAC Physical Function subscale (n=416)-8.0 ± 19.6
SecondaryPhysicians' Global Assessment of Patients' Response to Therapy at Baseline Using IGART (Investigator Global Assessment of Response to Therapy)

The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants who met the criteria of any of the 5 categories at baseline were collected.

Time frame:
Baseline
Reported as:
Number · Percentage of Participants
Physicians' Global Assessment of Patients' Response to Therapy at Baseline Using IGART (Investigator Global Assessment of Response to Therapy)
Percentage of ParticipantsEtoricoxib (Baseline)
No Response4.40
Poor Response57.60
Fair Response36.40
Good Response1.60
Excellent Response0.00
SecondaryPhysicians' Global Assessment of Patients' Response to Therapy at Week 4 Using IGART

The IGART comprised of five categories: No response, poor response, fair response, good response, and excellent response. The percentage of participants met the criteria of any of the 5 categories at week 4 were collected.

Time frame:
Week 4
Reported as:
Number · Percentage of Participants
Physicians' Global Assessment of Patients' Response to Therapy at Week 4 Using IGART
Percentage of ParticipantsEtoricoxib (Week 4)
No response5.81
Poor response16.05
Fair response35.35
Good response36.74
Excellent response6.05
PrimaryThe Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 4

WOMAC for pain assessment by patient (0-100 mm Visual Analog Scale (VAS) with 0 represent "no pain" and 100 represent "extreme pain")

Time frame:
Baseline and end of week 4
Reported as:
Number · Percentage of Participants
The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 4
Percentage of ParticipantsEtoricoxib
The Percentage of Participants Achieving ≥30% Decrease From Baseline in Pain Intensity as Measured by WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Question 1 "Pain Walking on a Flat Surface" at Week 452.04
SecondaryPatient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Baseline

The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[Not present, moderate and extreme\] for discomfort and anxiety/depression.

Time frame:
Baseline
Reported as:
Number · Percentage of Participants
Patient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Baseline
Percentage of ParticipantsBaseline - EQ-5D
Motility (n=499) No problem54.91
Motility (n=499) Some problem45.09
Motility (n=499) Not able to carry out0.00
Self care (n=499) No problem86.97
Self care (n=499) Some problem12.63
Self care (n=499) Not able to carry out0.40
Daily activity (n=499) No problem54.91
Daily activity (n=499) Some problem43.69
Daily activity (n=499) Not able to carry out1.40
Pain/Discomfort (n=500) Not present10.00
Pain/Discomfort (n=500) Moderate79.60
Pain/Discomfort (n=500) Extreme10.40
Anxiety/Depressed (n=500) Not present51.60
Anxiety/Depressed (n=500) Moderate44.00
Anxiety/Depressed (n=500) Extreme4.40
SecondaryPatient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Week 4

The percentage of participants who met the criteria of any of the 3 categories of EQ-5D at baseline and at week 4 were collected.The EQ-5D comprises of 5 dimensions (mobility, self-care, usual activities, pain / discomfort, and anxiety / depression) to be answered using a 3-categorical Likert's scales of: \[No problem, Some problem, and Not able to carry out\] for mobility, self-care and usual activities and \[ Not present, moderate and extreme\]for discomfort and anxiety/depression

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Patient Assessment of General Health Outcome by EuroQoL-5 Dimensions (EQ-5D) at Week 4
Percentage of participantsWeek 4 - EQ-5D
Motility (n=423) No problem67.61
Motility (n=423) Some problem32.39
Motility (n=423) Not able to carry out0.00
Self care (n=422) No problem90.05
Self care (n=422) Some problem9.48
Self care (n=422) Not able to carry out0.47
Daily activity (n=421) No problem61.76
Daily activity (n=421) Some problem37.29
Daily activity (n=421) Not able to carry out0.95
Pain/Discomfort (n=421) Not present23.04
Pain/Discomfort (n=421) Moderate73.63
Pain/Discomfort (n=421) Extreme3.33
Anxiety/Depressed (n=422) Not present61.37
Anxiety/Depressed (n=422) Moderate36.97
Anxiety/Depressed (n=422) Extreme1.66
SecondaryChange From Baseline of Patient BPI (Brief Pain Inventory) Scores at Week 4

BPI consists of pain and pain interference domains. For pain (0=no pain to 10=extreme pain); for pain interference ( 0=no interference to 10= greatest interference).

Time frame:
Baseline and Week 4
Reported as:
Mean · Units on a Scale
Change From Baseline of Patient BPI (Brief Pain Inventory) Scores at Week 4
Units on a ScaleEtoricoxib
BPI Worst pain (n=418)-1.5 ± 2.4
BPI Least pain (n=417)-0.6 ± 2.2
BPI Average pain (n=419)-1.0 ± 2.0
BPI Pain right now (n=416)-1.3 ± 2.6
BPI Interference on general activities (n=419)-0.8 ± 2.5
BPI Interference on Mood (n=419)-1.0 ± 2.7
BPI Interference on Walking (n=419)-1.2 ± 2.5
BPI Interference on Normal work (n=419)-1.1 ± 2.8
BPI Interference on Relations (n=418)-0.6 ± 2.6
BPI Interference on Sleep (n=419)-1.0 ± 2.8
BPI Interference on Enjoyment of life(n=419)-0.8 ± 2.7
SecondaryChanges From Baseline in Patient TSQM (Treatment Satisfaction Questionnaire for Medication) Domain Scores at Week 4

TSQM consists of four domains (effectiveness; side effect; convenience and overall satisfaction), domain scores ranged from 0 (0=worst) to 100 (100=best) were derived from converting the original Likert's scales to VAS scale.

Time frame:
Baseline and Week 4
Reported as:
Mean · Units on a Scale
Changes From Baseline in Patient TSQM (Treatment Satisfaction Questionnaire for Medication) Domain Scores at Week 4
Units on a ScaleEtoricoxib
Effectiveness ((n=418)2.8 ± 17.0
Side Effect (n=22)-3.8 ± 16.4
Convenience (n=418)0.9 ± 10.8
Overall (n=419)1.1 ± 20.9
SecondaryChange From Baseline in Number of Days Patient Miss From Work or House Keeping Work at Week 4
Time frame:
Baseline and Week 4
Reported as:
Mean · Days
Change From Baseline in Number of Days Patient Miss From Work or House Keeping Work at Week 4
DaysEtoricoxib
Days Missed From Work (n=138)-0.4 ± 1.6
Days Missed From Housekeeping Work (n=411)-2.3 ± 6.8
SecondaryChange From Baseline in Patient-SF36 (Short Form 36) Domain Scores at Week 4

Weighted scores of the 8 domains of SF36 (i.e., physical functioning; role limiting due to physical problem; bodily pain; general health; vitality; social functioning; role limiting due to emotional problem; mental health) were scored on a scale from 0 \~100, with 100 representing the best possible functioning)

Time frame:
Baseline and Week 4
Reported as:
Mean · Units on a Scale
Change From Baseline in Patient-SF36 (Short Form 36) Domain Scores at Week 4
Units on a ScaleEtoricoxib 60 mg q.d.
SF36 Physical Functioning (n=418)5.2 ± 19.9
SF36 Role Limiting Due to Physical Problem (n=418)17.6 ± 49.3
SF36 Bodily Pain (n=418)10.6 ± 17.7
SF36 General Health (n=419)2.0 ± 16.2
SF36 Vitality (n=417)1.4 ± 15.1
SF36 Social Functioning (n=419)8.7 ± 20.3
SF36 Role Limiting Due to Emotional Problem(n=418)14.0 ± 50.4
SF36 Mental Health (n=417)4.4 ± 14.0

Adverse events

Collected over From baseline to end of week 4. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etoricoxib—6/500 (1.2%)82/500 (16.4%)
Most frequent serious events
Most frequent serious events
EventEtoricoxib
Peritoneal adhesionGastrointestinal disorders1/500
Bacterial infectionInfections and infestations1/500
Lung abscess, chest pain/tightness and tremorGeneral disorders1/500
Traffic accidentInjury, poisoning and procedural complications1/500
UrethritisRenal and urinary disorders1/500
Respiratory failureRespiratory, thoracic and mediastinal disorders1/500
Most frequent other events
Most frequent other events
EventEtoricoxib
Edema , face/eye /hand/legVascular disorders24/500
DizzinessNervous system disorders11/500
Hypertension / elevated blood pressureVascular disorders9/500
PalpitationCardiac disorders8/500
Skin rashSkin and subcutaneous tissue disorders7/500
Abdominal distension / flatulenceGastrointestinal disorders6/500
Abdominal pain, upperGastrointestinal disorders6/500
NauseaGastrointestinal disorders6/500
HeadacheNervous system disorders5/500

Baseline characteristics

Age, Continuous
Age, Continuous(years)Etoricoxib
Mean66.6 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Etoricoxib
Female365
Male135
Patient-SF36 (Short form 36) domain scores
Patient-SF36 (Short form 36) domain scores(Units on a scale)Etoricoxib
SF-36 Physical functional45.1 ± 51.3
SF-36 Role limitation due to physical problem24.0 ± 42.5
SF-36 Bodily pain52.4 ± 63.9
SF-36 General health52.7 ± 54.5
SF-36 Vitality55.9 ± 57.6
SF-36 Social functioning69.0 ± 78.3
SF-36 Role limitation due to emotional problem41.3 ± 56.6
SF-36 Mental health61.7 ± 66.3
TSQM (Treatment Satisfaction Questionnaire for Medication )domain scores
TSQM (Treatment Satisfaction Questionnaire for Medication )domain scores(Units on a scale)Etoricoxib
TSQM - Effectiveness52.1 ± 55.6
TSQM - Side effect56.9 ± 55.7
TSQM - Convenience68.0 ± 68.8
TSQM - Overall satisfaction44.1 ± 45.7
The mean of patient BPI (Brief Pain Inventory) scores
The mean of patient BPI (Brief Pain Inventory) scores(Units on a scale)Etoricoxib
BPI -Worst pain6.4 ± 4.9
BPI -Least pain3.2 ± 2.5
BPI-Average pain4.9 ± 3.8
BPI -Pain right now4.4 ± 3.1
BPI -Interference on general activities2.9 ± 2.1
BPI - Mood3.2 ± 2.2
BPI -Walking4.3 ± 2.9
BPI - Normal work4.2 ± 2.9
BPI- Relations with other people2.5 ± 1.9
BPI - Sleep3.3 ± 2.3
BPI - Enjoyment of life3.0 ± 2.1
The mean of patient WOMAC ( Western Ontario and McMaster Universities Osteoarthritis Index) subscale
The mean of patient WOMAC ( Western Ontario and McMaster Universities Osteoarthritis Index) subscale(Units on a Scale)Etoricoxib
WOMAC Pain subscale38.5 ± 22.9
WOMAC Stiffness subscale36.3 ± 26.9
WOMAC Physical Function subscale38.0 ± 24.8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lin HY, Cheng TT, Wang JH, Lee CS, Chen MH, Lei V, Lac C, Gammaitoni AR, Smugar SS, Chen WJ. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010 May;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.x. PubMed 20536599 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2008
First posted
Sep 23, 2008
Start
Dec 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
May 11, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00757627
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 23, 2008
Start date
Dec 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
May 11, 2010
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion